Alain Parthoens
Directeur/Bestuurslid bij ACTICOR BIOTECH SAS
Oorsprong van het eerstegraads netwerk van Alain Parthoens
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 20 | |
| Subsidiary | Packaged Software | 13 | |
Ogeda SA
 Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain.
12
| Subsidiary | Pharmaceuticals: Major | 12 |
Apitope Technology (Bristol) Ltd.
 Apitope Technology (Bristol) Ltd. Miscellaneous Commercial ServicesCommercial Services Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies.
11
| Subsidiary | Miscellaneous Commercial Services | 11 |
Vesalius Biocapital Partners SARL
 Vesalius Biocapital Partners SARL Investment ManagersFinance Vesalius Biocapital Partners SARL (Vesalius Biocapital Partners) is an independent venture capital firm founded in 2007 by Stéphane Verdood. The firm is headquartered in Luxembourg.
10
| Private Company | Investment Managers | 10 |
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
7
| Holding Company | Pharmaceuticals: Major | 7 |
Ncardia Holding SA
 Ncardia Holding SA BiotechnologyHealth Technology Ncardia Holding SA provides biotech research and development, business management consulting, technical testing, and administrative services. The private company is based in Mont-Saint-Guibert, Belgium. The Belgian company was founded in 2014. Stefan Braam has been the CEO of the company since 2015.
6
| Private Company | Biotechnology | 6 |
Epics Therapeutics SA
 Epics Therapeutics SA Miscellaneous Commercial ServicesCommercial Services EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium.
5
| Holding Company | Miscellaneous Commercial Services | 5 |
ProFibrix BV
 ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands.
5
| Subsidiary | Biotechnology | 5 |
Biotechnological Enzymatic Catalyse NV
 Biotechnological Enzymatic Catalyse NV Food: Major DiversifiedConsumer Non-Durables Biotechnological Enzymatic Catalyse NV develops, produces and commercializes enzymatic systems for food preservation. It engages in the research, development and manufacturing of antimicrobial products for food safety. The firm's solutions are designed for use in the following: dairy products, fruit and vegetable juices, sauces and dressings and liquid egg products. The company was founded in 1992 and is headquartered in Ghent, Belgium.
5
| Holding Company | Food: Major Diversified | 5 |
Newton Biocapital Partners SRL
 Newton Biocapital Partners SRL Investment ManagersFinance Newton Biocapital Partners SPRL is an Independent Venture Capital firm founded in 2017 by Alain Parthoens. Newton Biocapital Partners SPRL is headquartered in Woluwe-Saint-Pierre.
4
| Private Company | Investment Managers | 4 |
The Belgian Venture Capital & Private Equity Association
 The Belgian Venture Capital & Private Equity Association Miscellaneous Commercial ServicesCommercial Services The Belgian Venture Capital & Private Equity Association provides equity capital to enterprises not quoted on a stock market. The firm develops new products and technologies to expand working capital, to make acquisitions or to strengthen a company’s balance sheet. The company was founded in 1986 and is headquartered in Brussels, Belgium.
4
| Private Company | Miscellaneous Commercial Services | 4 |
Tibotec Virco NV
 Tibotec Virco NV Miscellaneous Commercial ServicesCommercial Services Tibotec-Virco NV develops drugs and individualized disease management products. The firm also offers early stage research programs concentrating on the development of treatments for cancer, hepatitis C, and other infectious diseases. The company also provides HIV drug resistance testing and other analytical services in the United States, Japan, Europe, Canada, and Australia. It has operations in Belgium, North Carolina, Ireland, and the United Kingdom. It was founded in by Paul Stoffels in March, 2001 and is headquartered in Mechelen, Belgium.
2
| Subsidiary | Miscellaneous Commercial Services | 2 |
Vesalius Biocapital II Partners SARL
1
| Subsidiary | 1 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Alain Parthoens via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| SANOFI | Biotechnology | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| TIGENIX NV | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member Public Communications Contact Corporate Officer/Principal | |
| ORGENESIS INC. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
| UCB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| ACKERMANS & VAN HAAREN NV | Engineering & Construction | Corporate Officer/Principal Corporate Officer/Principal | |
BNP Paribas Fortis Private Equity Belgium NV
 BNP Paribas Fortis Private Equity Belgium NV Investment ManagersFinance BNP Paribas Fortis Private Equity Belgium NV is a Private Equity/Venture Capital firm, a subsidiary of BNP Paribas Fortis SA/NV founded in 1981. BNP Paribas Fortis Private Equity Belgium NV is headquartered in Brussels. | Investment Managers | Private Equity Investor Director/Board Member | |
| ATON | Pharmaceuticals: Major | Chairman Director of Finance/CFO Director of Finance/CFO | |
| VALERIO THERAPEUTICS | Pharmaceuticals: Major | Founder Director/Board Member Director/Board Member | |
Northwestern University
 Northwestern University Other Consumer ServicesConsumer Services Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. Northwestern has three campuses | College/University | Doctorate Degree Corporate Officer/Principal | |
| Ghent University | College/University | Doctorate Degree Corporate Officer/Principal | |
| Katholieke Universiteit Leuven | College/University | Graduate Degree Graduate Degree Undergraduate Degree Doctorate Degree Doctorate Degree | |
| Université Libre de Bruxelles | College/University | Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree Doctorate Degree Undergraduate Degree | |
| École Centrale Paris | College/University | Undergraduate Degree Undergraduate Degree Graduate Degree | |
| Vrije Universiteit Brussel | College/University | Graduate Degree Masters Business Admin | |
Mediahuis Partners NV
 Mediahuis Partners NV Publishing: Books/MagazinesConsumer Services Mediahuis Partners NV provides media solutions. It prints news, and operates radio and television networks. Its brands include Mediahuis, Gazet van Antwerpen, Het Belang van Limburg, De Standaard, Het Nieuwsblad de Gentenaar, Rondom, Corelio printing, Coldset Printing Partners, Vier, Vijf, Woestijnvis, Nostalgie, Rob TV, and Gezondheid.be. The company was founded on June 29, 1976 and is headquartered in Groot-Bijgaarden, Belgium. | Publishing: Books/Magazines | Director/Board Member Director/Board Member | |
Trod Medical NV
 Trod Medical NV Medical SpecialtiesHealth Technology Trod Medical NV develops and commercializes tools for use in the focal ablation of soft tissues. The company was founded by Andre Scattolin Faure on June 29, 2006 and is headquartered in Leuven, Belgium. | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member | |
BNP Paribas Fortis Private Equity Expansion NV
 BNP Paribas Fortis Private Equity Expansion NV Investment ManagersFinance Founded in 1983, BNP Paribas Fortis Private Equity Expansion NV is a private equity firm that operates as a subsidiary of BNP Paribas SA. The company is based in Brussels, Belgium. | Investment Managers | Director/Board Member Director/Board Member | |
| Université Catholique de Louvain | College/University | Doctorate Degree Undergraduate Degree Corporate Officer/Principal Doctorate Degree | |
Apitope International NV
 Apitope International NV BiotechnologyHealth Technology Apitope International NV develops therapeutic vaccines. It operates as a bio-pharmaceutical company that engages in developing peptide therapies. The firm specializes on the discovery and development of revolutionary disease modifying therapies for treating autoimmune and allergic diseases, including multiple sclerosis, and Graves’ disease, FVIII intolerance and uveitis. The company was founded by David Wraith in 2002 and is headquartered in Diepenbeek, Belgium. | Biotechnology | Director/Board Member Chairman Founder Chairman Chief Executive Officer Corporate Officer/Principal Director/Board Member Corporate Officer/Principal Chief Operating Officer | |
Minka Therapeutics SA
 Minka Therapeutics SA Pharmaceuticals: MajorHealth Technology Minka Therapeutics SA develops therapeutic products and diagnostic complementary to current antiretroviral therapy in the treatment of AIDS. The firm provides therapeutic and diagnostic solutions for diseases linked to the immune system through its research on immune dysregulations. The company was founded by Patrice Debre, Vincent Vieillard, Michel Klein, Joël Crouzet, and Robert L. Murphy in 2008 and is headquartered in Evry, France. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer | |
Amakem NV
 Amakem NV Medical/Nursing ServicesHealth Services Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Exact Imaging, Inc.
 Exact Imaging, Inc. Medical SpecialtiesHealth Technology Exact Imaging, Inc. provides high resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Its ExactVu micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use, affordability, and being an extension of the current urological workflow. The company was founded by Sam Ifergan and Randy AuCoin in 2013 and is headquartered in Markham, Canada. | Medical Specialties | Director/Board Member Director/Board Member | |
Eyevensys SAS
 Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Miscellaneous Commercial Services | Director/Board Member Chief Executive Officer | |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member | |
QBIC Venture Partners BV
 QBIC Venture Partners BV Investment ManagersFinance QBIC Venture Partners BVBA (QBIC Venture Partners) is a venture capital firm founded in 2012 by Marc Zabeau. The firm is headquartered in Belgium. | Investment Managers | Private Equity Investor Private Equity Investor | |
MaSTherCell SA
 MaSTherCell SA BiotechnologyHealth Technology MaSTherCell SA engages in providing cell therapy manufacturing services. The company was founded in 2011 and is headquartered in Charleroi, Belgium. | Biotechnology | Director/Board Member Director/Board Member Chief Executive Officer | |
Fast Forward Pharmaceuticals BV
 Fast Forward Pharmaceuticals BV Medical SpecialtiesHealth Technology Fast Forward Pharmaceuticals BV develops novel disease-modifying therapeutics for the treatment of inflammatory and autoimmune diseases. It is developing an anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn’s disease. The company was founded by Louis Boon in October 2010 and is headquartered in Utrecht, Netherlands. | Medical Specialties | Director/Board Member Director/Board Member | |
| Solvay Business School of Economics & Management | College/University | Undergraduate Degree Graduate Degree | |
| MINERVA NEUROSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Novadip Biosciences SA
 Novadip Biosciences SA BiotechnologyHealth Technology Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
| Centre Hospitalier Universitaire de Liege | College/University | Doctorate Degree Undergraduate Degree | |
Fund+
 Fund+ Investment ManagersFinance Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium. | Investment Managers | Private Equity Investor Private Equity Investor | |
| Roche SAS | President Corporate Officer/Principal | ||
eTheRNA immunotherapies NV
 eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
Horama SA
 Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | Biotechnology | Director/Board Member Director/Board Member | |
PharmaFluidics NV
 PharmaFluidics NV Electronic Equipment/InstrumentsElectronic Technology Pharmafluidics NV develops micro chip liquid chromatography cartridges for analysis of complex biological samples. The company was founded by Wim De Malsche, Joeri Denayer, Gert Desme and Paul Godelieve Jacobs in 2010 and is headquartered in Ghent, Belgium. | Electronic Equipment/Instruments | Chairman Director/Board Member Director/Board Member | |
DIM3 SA
 DIM3 SA Packaged SoftwareTechnology Services DIM3 SA develops decision support application software and medical devices. The firm offers Scorso, an app for the screening and follow-up of disease-related malnutrition; Nutrow, a decision support software for an optimization of clinical nutrition; and Biocorder, a connected clinical mobile assistant. The company was founded by Jean Claude Havaux on September 23, 2004 and is headquartered in Liege, Belgium. | Packaged Software | Chairman Director/Board Member | |
Ncardia SA
 Ncardia SA Miscellaneous Commercial ServicesCommercial Services Ncardia SA engages in drug discovery research and development. Its cardiac products encompass hiPSC-derived Pluricyte, Cardiomyocytes, Cor.4U cardiomyocytes and vCor.4U ventricular cardiomyocytes and FibroCor.4U cardiac fibroblasts. The company is headquartered in Gosselies, Belgium. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member Founder | |
| Voluntis, Inc. | President Corporate Secretary | ||
NeuVasQ Biotechnologies SA
 NeuVasQ Biotechnologies SA Pharmaceuticals: MajorHealth Technology NeuVasQ Biotechnologies SA develops pharmaceutical products to treat neurological disorders by repairing neurovascular function. The company is based in Gosselies, Belgium. The Belgian company was founded in 2021 by Benoit Vanhollebeke. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| EUROAPI | Biotechnology | Director/Board Member Chairman |
Statistieken
Internationaal
| België | 30 |
| Frankrijk | 13 |
| Verenigde Staten | 6 |
| Nederland | 3 |
| Canada | 2 |
Sectoraal
| Health Technology | 25 |
| Consumer Services | 13 |
| Finance | 7 |
| Commercial Services | 3 |
| Industrial Services | 2 |
Operationeel
| Director/Board Member | 430 |
| Corporate Officer/Principal | 141 |
| Independent Dir/Board Member | 60 |
| Chief Executive Officer | 44 |
| Chairman | 38 |
Sterkste connecties
| Insiders | |
|---|---|
| Alain Munoz | 38 |
| Francesco de Rubertis | 36 |
| Koen Janssen | 34 |
| Jean-Paul Prieels | 32 |
| Stéphane Verdood | 32 |
| André-Xavier Cooreman | 25 |
| Jan Berger | 22 |
| Viviane Monges | 21 |
| Michel Allé | 20 |
| William John Jenkins | 20 |
| Corinne Le Goff | 19 |
| Catherine Boule | 18 |
| Christian Schneider | 17 |
| Guy Heynen | 17 |
| Nico Vandervelpen | 17 |
- Beurs
- Insiders
- Alain Parthoens
- Bedrijfsconnecties
